These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 26986253

  • 1. Pre-diagnostic circulating sex hormone levels and risk of prostate cancer by ERG tumour protein expression.
    Graff RE, Meisner A, Ahearn TU, Fiorentino M, Loda M, Giovannucci EL, Mucci LA, Pettersson A.
    Br J Cancer; 2016 Apr 12; 114(8):939-44. PubMed ID: 26986253
    [Abstract] [Full Text] [Related]

  • 2. Prospective study of sex hormone levels and risk of prostate cancer.
    Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ.
    J Natl Cancer Inst; 1996 Aug 21; 88(16):1118-26. PubMed ID: 8757191
    [Abstract] [Full Text] [Related]

  • 3. Circulating Antioxidant Levels and Risk of Prostate Cancer by TMPRSS2:ERG.
    Graff RE, Judson G, Ahearn TU, Fiorentino M, Loda M, Giovannucci EL, Mucci LA, Pettersson A.
    Prostate; 2017 May 21; 77(6):647-653. PubMed ID: 28102015
    [Abstract] [Full Text] [Related]

  • 4. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era.
    Platz EA, Leitzmann MF, Rifai N, Kantoff PW, Chen YC, Stampfer MJ, Willett WC, Giovannucci E.
    Cancer Epidemiol Biomarkers Prev; 2005 May 21; 14(5):1262-9. PubMed ID: 15894683
    [Abstract] [Full Text] [Related]

  • 5. Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer.
    Cornu JN, Cancel-Tassin G, Egrot C, Gaffory C, Haab F, Cussenot O.
    Prostate; 2013 Feb 15; 73(3):242-9. PubMed ID: 22821767
    [Abstract] [Full Text] [Related]

  • 6. A Prospective Study of the Association between Physical Activity and Risk of Prostate Cancer Defined by Clinical Features and TMPRSS2:ERG.
    Pernar CH, Ebot EM, Pettersson A, Graff RE, Giunchi F, Ahearn TU, Gonzalez-Feliciano AG, Markt SC, Wilson KM, Stopsack KH, Gazeeva E, Lis RT, Parmigiani G, Rimm EB, Finn SP, Giovannucci EL, Fiorentino M, Mucci LA.
    Eur Urol; 2019 Jul 15; 76(1):33-40. PubMed ID: 30301696
    [Abstract] [Full Text] [Related]

  • 7. Obesity and Prostate Cancer Risk According to Tumor TMPRSS2:ERG Gene Fusion Status.
    Egbers L, Luedeke M, Rinckleb A, Kolb S, Wright JL, Maier C, Neuhouser ML, Stanford JL.
    Am J Epidemiol; 2015 May 01; 181(9):706-13. PubMed ID: 25852077
    [Abstract] [Full Text] [Related]

  • 8. Intratumoral androgen levels are linked to TMPRSS2-ERG fusion in prostate cancer.
    Knuuttila M, Mehmood A, Mäki-Jouppila J, Ryberg H, Taimen P, Knaapila J, Ettala O, Boström PJ, Ohlsson C, Venäläinen MS, Laiho A, Elo LL, Sipilä P, Mäkelä SI, Poutanen M.
    Endocr Relat Cancer; 2018 Sep 01; 25(9):807-819. PubMed ID: 29773553
    [Abstract] [Full Text] [Related]

  • 9. Morphological features of TMPRSS2-ERG gene fusion prostate cancer.
    Mosquera JM, Perner S, Demichelis F, Kim R, Hofer MD, Mertz KD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, Rubin MA.
    J Pathol; 2007 May 01; 212(1):91-101. PubMed ID: 17385188
    [Abstract] [Full Text] [Related]

  • 10. A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer.
    Ahearn TU, Pettersson A, Ebot EM, Gerke T, Graff RE, Morais CL, Hicks JL, Wilson KM, Rider JR, Sesso HD, Fiorentino M, Flavin R, Finn S, Giovannucci EL, Loda M, Stampfer MJ, De Marzo AM, Mucci LA, Lotan TL.
    J Natl Cancer Inst; 2016 Feb 01; 108(2):. PubMed ID: 26615022
    [Abstract] [Full Text] [Related]

  • 11. The TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancer.
    Graff RE, Pettersson A, Lis RT, DuPre N, Jordahl KM, Nuttall E, Rider JR, Fiorentino M, Sesso HD, Kenfield SA, Loda M, Giovannucci EL, Rosner B, Nguyen PL, Sweeney CJ, Mucci LA, Transdisciplinary Prostate Cancer Partnership ToPCaP.
    Prostate; 2015 Jun 15; 75(9):897-906. PubMed ID: 25728532
    [Abstract] [Full Text] [Related]

  • 12. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
    Hermans KG, van Marion R, van Dekken H, Jenster G, van Weerden WM, Trapman J.
    Cancer Res; 2006 Nov 15; 66(22):10658-63. PubMed ID: 17108102
    [Abstract] [Full Text] [Related]

  • 13. Prevalence and prognostic significance of TMPRSS2-ERG gene fusion in lymph node positive prostate cancers.
    Fleischmann A, Saramäki OR, Zlobec I, Rotzer D, Genitsch V, Seiler R, Visakorpi T, Thalmann GN.
    Prostate; 2014 Dec 15; 74(16):1647-54. PubMed ID: 25252136
    [Abstract] [Full Text] [Related]

  • 14. Dietary lycopene intake and risk of prostate cancer defined by ERG protein expression.
    Graff RE, Pettersson A, Lis RT, Ahearn TU, Markt SC, Wilson KM, Rider JR, Fiorentino M, Finn S, Kenfield SA, Loda M, Giovannucci EL, Rosner B, Mucci LA.
    Am J Clin Nutr; 2016 Mar 15; 103(3):851-60. PubMed ID: 26817504
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Circulating steroid hormones and the risk of prostate cancer.
    Severi G, Morris HA, MacInnis RJ, English DR, Tilley W, Hopper JL, Boyle P, Giles GG.
    Cancer Epidemiol Biomarkers Prev; 2006 Jan 15; 15(1):86-91. PubMed ID: 16434592
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.